Overview
This quality standard covers the identification and management of familial and genetic risk and the recognition and management of ovarian, fallopian tube and primary peritoneal cancer or borderline ovarian cancer in women, trans men and non-binary people aged 18 and over with female reproductive organs (ovaries, fallopian tubes or a uterus). It describes high-quality care in priority areas for improvement.
The quality standard does not cover risk management and decision-making support for men, trans women and non-binary adults born with male reproductive organs who have, or are at risk of having, a pathogenic variant associated with ovarian cancer.
Last reviewed: 15 April 2026
This quality standard was updated, and the placeholder statement (statement 2) prioritised in 2025 was updated alongside the publication of updated recommendations in NICE’s guideline on suspected cancer to support it. For more information, see update information.
How to use NICE quality standards and how we develop them
Quality standards help you improve the quality of care you provide or commission. They apply in England and Wales (see the UK government website and Welsh government website). Decisions on how they apply in Scotland and Northern Ireland are made by ministers in the Scottish government and Northern Ireland Executive.
Find out how to use quality standards and how we develop them.
Endorsing bodies
This quality standard is endorsed by NHS England as required by the Health and Social Care Act (2012).
Supporting organisations
A number of organisations recognise the benefit of this quality standard in improving care. They work with us to promote it to commissioners and service providers: